Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
复制标题
ABCB1 化疗治疗上皮性卵巢癌的预后价值和意义：荟萃分析
DOI：
10.1371/journal.pone.0166058
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Wang Z
中科院分区：
文献类型：
--
作者：
Sun S;Cai J;Yang Q;Zhu Y;Zhao S;Wang Z
背景：化疗耐药与上皮性卵巢癌（EOC）中抗肿瘤药物转运蛋白ABCB 1（p-gp）表达上调有关，但结果仍存在争议。为了协调结果，进行了一项系统性综述，随后进行了荟萃分析，以评估EOC患者的高ABCB 1状态或ABCB 1基因变异与总生存期（OS）、无进展生存期（PFS）和总缓解率（TR）之间的相关性。材料与方法电子检索Pubmed、EMBASE、Web of Science和中国万方数据库1990 - 01/2016 - 02。酌情使用固定或随机效应模型合并汇总风险比（HR）、风险比（RR）和95%置信区间（CI）。结果共纳入38篇回顾性研究，纳入8607例病例。我们的研究结果表明，ABCB 1过表达与不利的OS（HR = 1.54; 95%CI，1.25-1.90），PFS（HR = 1.49; 95%CI，1.22-1.82）和TR（RR = 0.63; 95%CI，0.54-0.75）显著相关。校正年龄、临床分期、残留病灶、组织学类型和肿瘤分级后，高ABCB 1状态仍然是不良OS和PFS的重要风险因素。复发性ABCB 1阳性患者的OS比原发性ABCB 1阳性患者差。然而，按化疗方案分层，仅在接受铂类药物化疗的患者中发现高ABCB 1状态与OS、PFS和TR较差呈负相关，而在接受标准铂类/紫杉醇化疗的患者中未发现。没有证据表明ABCB 1基因多态性与OS、PFS或TR之间存在任何关联。结论卵巢癌患者ABCB 1高表达与化疗耐药及预后不良密切相关。需要大规模的前瞻性研究来更准确地评估ABCB 1在EOC中表达的临床价值。
Background Chemotherapy resistance is reported to correlate with up-regulation of anti-tumor agent transporter ABCB1 (p-gp) in epithelial ovarian cancer (EOC), but the results remain controversial. To reconcile the results, a systematic review followed by meta-analysis was performed to assess the association between high ABCB1 status or ABCB1 gene variants and overall survival (OS), progression free survival (PFS), and total response rate (TR) in patients with EOC. Materials and Methods Electronic searches were performed using Pubmed, EMBASE, Web of Science and Chinese Wanfang databases from January 1990 to February 2016. Summary hazard ratio (HR), risk ratio (RR) and 95% confidence intervals (CIs) were combined using fixed or random-effects models as appropriate. Results Thirty-eight retrospective studies of 8607 cases qualified for meta-analysis were identified. Our results suggested that ABCB1 over-expression was significantly associated with unfavorable OS (HR = 1.54; 95% CI, 1.25–1.90), PFS (HR = 1.49; 95% CI, 1.22–1.82) and TR (RR = 0.63; 95% CI, 0.54–0.75). After adjustment for age, clinical stage, residual disease, histological type and tumor grade, high ABCB1 status remained to be a significant risk factor for adverse OS and PFS. Patients with recurrent ABCB1 positivity suffered from poorer OS than those with primary ABCB1 positivity. However, stratified by chemotherapy regimen, inverse correlation between high ABCB1 status and poor OS, PFS and TR were only found in patients underwent platinum-based chemotherapy but not in patients received standard platinum/paclitaxel-based chemotherapy. No evidence was found for any association between ABCB1 gene polymorphisms and OS, PFS or TR. Conclusion High ABCB1 status is significantly associated with chemo-resistance and poor prognosis in patients with EOC. Large-scale, prospective studies are needed to assess the clinical value of ABCB1 expression in EOC more accurately.
登录
查看更多内容
影响因子：
4.7
作者：
Codegoni, AM;Broggini, M;DIncalci, M
通讯作者：
DIncalci, M
影响因子：
2.9
作者：
Bergmann, Troels K.;Green, Henrik;Peterson, Curt
通讯作者：
Peterson, Curt
DOI：
10.1038/nrc4019
发表时间：
2015-11
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Bowtell DD;Böhm S;Ahmed AA;Aspuria PJ;Bast RC Jr;Beral V;Berek JS;Birrer MJ;Blagden S;Bookman MA;Brenton JD;Chiappinelli KB;Martins FC;Coukos G;Drapkin R;Edmondson R;Fotopoulou C;Gabra H;Galon J;Gourley C;Heong V;Huntsman DG;Iwanicki M;Karlan BY;Kaye A;Lengyel E;Levine DA;Lu KH;McNeish IA;Menon U;Narod SA;Nelson BH;Nephew KP;Pharoah P;Powell DJ Jr;Ramos P;Romero IL;Scott CL;Sood AK;Stronach EA;Balkwill FR
通讯作者：
Balkwill FR
DOI：
10.3322/caac.20113
发表时间：
2011-05
期刊：
CA: a cancer journal for clinicians
影响因子：
--
作者：
Jelovac D;Armstrong DK
通讯作者：
Armstrong DK
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N